Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Respir Cell Mol Biol ; 24(2): 116-22, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11159044

ABSTRACT

The unique role of interleukin (IL)-5 in eosinophil production, activation, and localization makes this cytokine a prime target for therapeutic intervention in diseases characterized by a selective blood and tissue eosinophilia. In an attempt to block the effects of IL-5 on eosinophils, a strategy was developed to suppress the expression of the IL-5 receptor alpha chain (IL-5Ralpha) by antisense oligonucleotides (ASOs). IL-5Ralpha ASOs were identified which selectively and specifically suppress the expression of messenger RNA and proteins of both the membrane and the soluble form of the receptor in constitutively IL-5R-expressing murine BCL-1 cells in vitro. Moreover, these IL-5Ralpha-specific ASOs were able to selectively inhibit the IL-5-induced eosinopoesis from murine fetal liver and bone marrow cells in vitro, suggesting that these molecules may affect the development of IL-5-mediated eosinophilia in vivo. Indeed, intravenous administration of IL-5Ralpha-specific ASOs not only suppressed the bone-marrow and blood eosinophilia in mice after short-term treatment with recombinant murine IL-5 but also inhibited the development of blood and tissue eosinophilia in a ragweed-induced allergic peritonitis model. Thus, blocking the expression of IL-5Ralpha on eosinophil using ASOs may have therapeutic benefits in eosinophilic diseases such as asthma.


Subject(s)
Eosinophilia/prevention & control , Eosinophils/metabolism , Interleukin-5/pharmacology , Oligonucleotides, Antisense/pharmacology , Receptors, Interleukin/antagonists & inhibitors , Animals , Blotting, Northern , Blotting, Western , Bone Marrow/drug effects , Bone Marrow/metabolism , DNA Primers/chemistry , Eosinophilia/metabolism , Female , Humans , In Vitro Techniques , Liver/drug effects , Liver/metabolism , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Peritonitis/genetics , Peritonitis/pathology , RNA, Messenger/antagonists & inhibitors , RNA, Messenger/biosynthesis , Receptors, Interleukin/metabolism , Receptors, Interleukin-5 , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction/drug effects , Transfection , Tumor Cells, Cultured
2.
Blood ; 96(7): 2506-10, 2000 Oct 01.
Article in English | MEDLINE | ID: mdl-11001904

ABSTRACT

The tyrosine kinase Syk has been proposed to play a critical role in the antiapoptotic effect of interleukin (IL)-5 in human eosinophils. However, little is known about the involvement of Syk in other IL-5-mediated activation events. To further address these questions, the role of Syk in IL-5-induced eosinophil differentiation, activation, and survival was analyzed using cells obtained from Syk-deficient mice. We could demonstrate that Syk-deficient fetal liver cells differentiate into mature eosinophils in response to IL-5 at the same rate as wild-type fetal liver cells and generate the same total number of eosinophils. Moreover, no difference in IL-5-induced survival of mature eosinophils between Syk(-/-) and wild-type eosinophils could be demonstrated, suggesting that the antiapoptotic effect of IL-5 does not require Syk despite the activation of this tyrosine kinase upon IL-5 receptor ligation. In contrast, eosinophils derived from Syk-deficient but not wild-type mice were incapable of generating reactive oxygen intermediates in response to Fcgamma receptor (FcgammaR) engagement. Taken together, these data clearly demonstrate no critical role for Syk in IL-5-mediated eosinophil differentiation or survival but underline the importance of this tyrosine kinase in activation events induced by FcgammaR stimulation.


Subject(s)
Cell Differentiation , Cell Survival , Enzyme Precursors/deficiency , Eosinophils/enzymology , Interleukin-5/pharmacology , Protein-Tyrosine Kinases/deficiency , Receptors, Fc/physiology , Animals , Apoptosis , Enzyme Activation , Enzyme Precursors/physiology , Eosinophils/cytology , Intracellular Signaling Peptides and Proteins , Liver/cytology , Liver/embryology , Liver/enzymology , Mice , Protein-Tyrosine Kinases/physiology , Reactive Oxygen Species/metabolism , Respiratory Burst , Syk Kinase
3.
J Immunol ; 162(12): 7549-54, 1999 Jun 15.
Article in English | MEDLINE | ID: mdl-10358211

ABSTRACT

The low levels of complement receptor 1 (CR1) on erythrocytes in autoimmune diseases and AIDS may be due to accelerated loss in the circulation, or to a diminished expression of CR1 on the red cell lineage. Therefore, we analyzed the expression of CR1 on reticulocytes (R) vs erythrocytes (E). Healthy subjects had a significant higher CR1 number per cell on R (919 +/- 99 CR1/cell) than on E (279 +/- 30 CR1/cell, n = 23), which corresponded to a 3. 5- +/- 1.3-fold loss of CR1. This intravascular loss was confirmed by FACS analysis, which showed that all R expressed CR1, whereas a large fraction of E was negative. The systemic lupus erythematosus (SLE), HIV-infected, and cold hemolytic Ab disease (CHAD) patients had a CR1 number on R identical to the healthy subjects, contrasting with a lower CR1 on their E. The data indicated a significantly higher loss of CR1 in the three diseases, i.e., 7.0- +/- 3.8-, 6.1- +/- 2.9-, and 9.6- +/- 5.6-fold, respectively. The intravascular loss was best exemplified in a patient with factor I deficiency whose CR1 dropped from 520 CR1/R to 28 CR1/E, i.e., 18.6-fold loss. In one SLE patient and in the factor I-deficient patient, the FACS data were consistent with a loss of CR1 already on some R. In conclusion, CR1 is lost progressively from normal E during in vivo aging so that old E are almost devoid of CR1. The low CR1 of RBC in autoimmune diseases and HIV-infection is due to a loss occurring in the circulation by an active process that remains to be defined.


Subject(s)
HIV Infections/immunology , Lupus Erythematosus, Systemic/immunology , Receptors, Complement 3b/biosynthesis , Reticulocytes/metabolism , Agglutinins/blood , Aging/blood , Aging/immunology , Anemia, Hemolytic, Autoimmune/blood , Anemia, Hemolytic, Autoimmune/immunology , Cryoglobulins , Enzyme-Linked Immunosorbent Assay , Erythrocytes/metabolism , HIV Infections/blood , Humans , Immunoblotting , Lupus Erythematosus, Systemic/blood , Receptors, Complement 3b/blood , Receptors, Complement 3b/physiology , Reticulocytes/immunology , Reticulocytes/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...